Save Product
Product Details
- ProductSizeAmountCellectra™ Human CD14 NanoSort Microbeads, Research grade2 mLFor 10⁹ total cells
Product Description
Cellectra™ Human CD14 NanoSort Microbeads, Research grade are dextran-coated superparamagnetic iron oxide nanoparticles of which the surface is conjugated with recombinant monoclonal antibodies specific to human CD14 (Isotype: mouse IgG2a). They are especially designed for positive selection of CD14+ cells.
Cellectra™ Human CD14 NanoSort Microbeads, Research grade are produced under sterile manufacturing conditions (ISO 5), and no animal- or human-derived components are used throughout the production process. It is produced under our rigorous quality control system that includes a comprehensive set of tests including sterility and endotoxin tests.Application
Cellectra™ Human CD14 NanoSort Microbeads, Research grade are designed for the positive selection of monocytes and macrophages from fresh or frozen human peripheral blood mononuclear cells (PBMCs). CD14, a glycosylphosphatidylinositol (GPI)-anchored membrane protein, is predominantly expressed on the surface of human monocytes and macrophages. The magnetic Microbeads are conjugated with monoclonal antibodies targeting human CD14 protein, enabling CD14+ cells to be labeled with the specific antibodies and magnetic particles, and separated using the separation columns and magnets.
Storage
For long term storage, the product should be stored in liquid state at -20°C or below Stability upon receipt: 1. Stable for 24 months at -20 °C or below; 2. Stable for 9 months at 2–8 °C under sterile conditions.
Please protect from light and avoid repeated freeze-thaw cycles.
Sterility
Negative
Endotoxin
Less than 2 EU per mL by the LAL method / rFC method.
Mycoplasma
Negative
Important Note
This product is for research use only and not intended for therapeutic or in vivo diagnostic use.
Formulation
Supplied in PBS buffer containing EDTA, rHSA and Poloxamer 188.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Application Data
Superior Cell Separation Performance (Comparison with Company M)
Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD14 microbeads from Acro, Company M at recommended dosages. Positive and negative fractions were collected, and 1×10⁶ cells from each fraction were immunostained with PE-conjugated anti-human CD14 antibody and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 98.01% (baseline: 22.03%), with a target cell residue of only 0.40% in the negative fraction. These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to Company M benchmarks.
Comparison of Cell Separation Performances
Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD14 NanoSort Microbeads, in parallel with Company M. The comparative analysis demonstrated that Acro NanoSort Microbeads is consistent with Company M. Furthermore, high post-isolation cell viability was preserved, confirming suitability for sensitive downstream applications.
Cell Separation Performances after Freeze-Thawing and Accelerated Aging at 37℃
Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing. Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use).
Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles. Following 4 and 7-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Monocyte differentiation antigen CD14
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
3 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
